IN2014MN00873A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00873A
IN2014MN00873A IN873MUN2014A IN2014MN00873A IN 2014MN00873 A IN2014MN00873 A IN 2014MN00873A IN 873MUN2014 A IN873MUN2014 A IN 873MUN2014A IN 2014MN00873 A IN2014MN00873 A IN 2014MN00873A
Authority
IN
India
Prior art keywords
antibodies
antibody fragments
antibody
specific
protein
Prior art date
Application number
Inventor
Gal Markel
Moshe Tehila Ben
Yair Sapir
Ilana Mandel
Jacob Schachter
Rona Ortenberg
Original Assignee
Tel Hashomer Medical Res Infrastructure & Services Ltd
Ccam Biotherapeutics Ltd
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Hashomer Medical Res Infrastructure & Services Ltd, Ccam Biotherapeutics Ltd, Univ Ramot filed Critical Tel Hashomer Medical Res Infrastructure & Services Ltd
Publication of IN2014MN00873A publication Critical patent/IN2014MN00873A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)

Abstract

The present invention provides antibodies as well as molecules having at least the antigen binding portion of an antibody recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis of such antibodies and antibody fragments are also provided.
IN873MUN2014 2011-10-11 2012-10-10 IN2014MN00873A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IL2011/000808 WO2013054320A1 (en) 2011-10-11 2011-10-11 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
PCT/IL2012/050402 WO2013054331A1 (en) 2011-10-11 2012-10-10 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)

Publications (1)

Publication Number Publication Date
IN2014MN00873A true IN2014MN00873A (en) 2015-07-03

Family

ID=48081453

Family Applications (1)

Application Number Title Priority Date Filing Date
IN873MUN2014 IN2014MN00873A (en) 2011-10-11 2012-10-10

Country Status (15)

Country Link
US (3) US9771431B2 (en)
EP (2) EP2744829B1 (en)
JP (1) JP6170926B2 (en)
KR (1) KR102189409B1 (en)
CN (1) CN103987729B (en)
AU (1) AU2012322272C1 (en)
BR (1) BR112014008893B1 (en)
CA (1) CA2851762C (en)
ES (2) ES2661488T3 (en)
IL (1) IL231931B (en)
IN (1) IN2014MN00873A (en)
LT (1) LT2744829T (en)
PL (2) PL3360899T3 (en)
RU (1) RU2650869C2 (en)
WO (2) WO2013054320A1 (en)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735157B2 (en) * 2005-06-09 2014-05-27 Gal Markel CEACAM1 mediated protective immunity
PL2990421T3 (en) * 2009-04-30 2018-08-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. ANTI-CEACAM1 ANTIBODIES AND METHODS OF THEIR USE
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
MX375221B (en) 2013-11-25 2025-03-06 Famewave Ltd Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
WO2015075710A1 (en) * 2013-11-25 2015-05-28 Ccam Biotherapeutics Ltd. Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US20170044268A1 (en) * 2013-12-23 2017-02-16 OncoMed Pharmaceuticals Immunotherapy with Binding Agents
WO2015101996A1 (en) * 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
ES2716685T3 (en) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Antibody molecules for PD-1 and uses thereof
DK3099717T3 (en) 2014-01-31 2019-07-01 Novartis Ag ANTISTOF MOLECULES WITH TIME 3 AND THEIR USES
TWI777174B (en) 2014-03-14 2022-09-11 瑞士商諾華公司 Antibody molecules to lag-3 and uses thereof
JP2017513818A (en) 2014-03-15 2017-06-01 ノバルティス アーゲー Treatment of cancer using chimeric antigen receptors
SI3888674T1 (en) 2014-04-07 2024-08-30 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
AP2016009504A0 (en) * 2014-04-27 2016-10-31 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
RU2020117196A (en) 2014-08-19 2020-10-15 Новартис Аг CHIMERIC ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN THE TREATMENT OF MALIGNANT TUMORS
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
JP6839074B2 (en) 2014-09-17 2021-03-03 ノバルティス アーゲー Targeting cytotoxic cells at chimeric receptors for adoptive immunotherapy
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
UY36351A (en) 2014-10-14 2016-06-01 Novartis Ag ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2016120331A1 (en) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistic anti-cd66cd66 antibody for antiviral therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
CN108025051B (en) 2015-07-29 2021-12-24 诺华股份有限公司 Combination therapy comprising anti-PD-1 antibody molecules
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
LT3317301T (en) 2015-07-29 2021-07-26 Novartis Ag Combination therapies comprising antibody molecules to lag-3
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
SMT202200118T1 (en) 2015-11-03 2022-05-12 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
ES2986067T3 (en) 2015-12-17 2024-11-08 Novartis Ag Antibody molecules against PD-1 and their uses
UY37030A (en) 2015-12-18 2017-07-31 Novartis Ag ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN107345968A (en) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 Purposes of the CECAM1 albumen as serum markers in diagnosing hepatic diseases
CN107345969A (en) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 Purposes of the serum markers comprising AFP, GP73 and CEACAM1 in diagnosing hepatic diseases
CN116769050A (en) 2016-07-20 2023-09-19 犹他大学研究基金会 CD229 CAR T cells and methods of use thereof
WO2018019380A1 (en) * 2016-07-28 2018-02-01 Universität Duisburg-Essen Immunostimulatory anti-ceacam1 antibodies
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
WO2018102786A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for modulation of car-t cells
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
KR102019913B1 (en) * 2017-03-24 2019-09-09 재단법인 목암생명과학연구소 Anti-ceacam1 antibody and use thereof
CN110475788A (en) 2017-03-24 2019-11-19 财团法人牧岩生命科学研究所 Anti-CEACAM1 antibody and its application
KR102325944B1 (en) * 2017-11-30 2021-11-12 재단법인 목암생명과학연구소 Anti-ceacam1 antibody and use thereof
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
KR20200054160A (en) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 Preparation and method of articles for treatment with adoptive cell therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
KR20200074997A (en) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 Antibodies and chimeric antigen receptors specific for B-cell maturation antigens
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102845789B1 (en) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 Chimeric antigen receptor and encoding polynucleotide specific for B cell maturation antigen
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20200128014A (en) 2018-01-31 2020-11-11 셀진 코포레이션 Adoptive cell therapy and combination therapy with checkpoint inhibitors
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3798227A4 (en) * 2018-05-09 2022-03-02 Good T Cells, Inc. REGULATORY T LYMPHOCYTE SURFACE ANTIGEN EPITOPE AND ANTIBODY SPECIFICALLY BINDING TO IT
JP7438988B2 (en) 2018-06-13 2024-02-27 ノバルティス アーゲー BCMA chimeric antigen receptor and its use
CN110684107B (en) * 2018-07-06 2021-03-23 中国人民解放军第四军医大学 Monoclonal antibody (MGd1) against MG7-Ag and use thereof
CN110684108B (en) * 2018-07-06 2021-06-04 中国人民解放军第四军医大学 anti-MG 7-Ag monoclonal antibody (CEA37) and application thereof
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
MX2021005024A (en) 2018-11-01 2021-07-21 Juno Therapeutics Inc TREATMENT METHODS USING SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CELL MATURATION ANTIGEN B.
CA3116413A1 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
SG11202105084VA (en) 2018-11-16 2021-06-29 Juno Therapeutics Inc Methods of dosing engineered t cells for the treatment of b cell malignancies
FI3886875T3 (en) 2018-11-30 2024-07-23 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
JP2022513729A (en) * 2018-12-07 2022-02-09 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド Humanized and affinity matured anti-CEACAM1 antibody
EP3898694A4 (en) * 2018-12-20 2023-02-15 Albert Einstein College of Medicine CEACAM1 (CD66A) HUMAN IMMUNE CHECKPOINT ANTAGONIST ANTIBODIES AND THEIR FORMULATIONS, KITS AND METHODS OF USE
KR102166982B1 (en) * 2019-01-24 2020-10-16 가톨릭대학교 산학협력단 Correlation of CEACAM1 and EpCAM in liver cancer and Methods for providing information for liver cancer therapeutic effect using using the same
CN113365660A (en) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1(ROR1)
TW202100560A (en) * 2019-06-04 2021-01-01 大陸商上海吉倍生物技術有限公司 Anti-ceacam5 monoclonal antibody, preparation method therefor and use thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CA3158635A1 (en) * 2019-11-07 2021-05-14 Green Cross Corporation Steric epitope of ceacam1, and anti-ceacam1 antibody, or fragment thereof, that specifically binds to same
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
BR112022020333A2 (en) 2020-04-10 2022-11-22 Juno Therapeutics Inc METHODS AND USES RELATED TO CELL THERAPY DESIGNED WITH A CHIMERIC ANTIGEN RECEPTOR THAT TARGETS B CELL MATURATION ANTIGEN
EP3909601A1 (en) * 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
EP4652997A3 (en) 2020-05-19 2026-03-04 Pharmacosmos Holding A/s Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
CN111675750B (en) * 2020-06-11 2022-08-30 中国药科大学 Tumor targeting peptide aiming at carcinoembryonic antigen related adhesion molecule CEACAM and application thereof
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
CN112028997B (en) * 2020-08-04 2021-08-13 中山大学附属第五医院 Anti-CEACAM5 Nanobody
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS
WO2022040470A1 (en) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
EP4201961A4 (en) * 2020-08-21 2024-07-03 Shanghai Genbase Biotechnology Co., Ltd. Antibody specifically bound to glycosylated ceacam5
WO2022041745A1 (en) * 2020-08-28 2022-03-03 安源医药科技（上海）有限公司 Antibody against sars-cov-2 coronavirus s protein and application thereof
JP7787164B2 (en) 2020-09-23 2025-12-16 アキリオン ファーマシューティカルズ， インコーポレーテッド Pharmaceutical compounds for the treatment of complement-mediated disorders
CN116621980B (en) * 2020-10-21 2025-10-28 北京纽安博生物技术有限公司 Anti-CEACAM6 single-domain antibody and its fusion protein and application
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022147509A1 (en) * 2021-01-04 2022-07-07 City Of Hope Prevention and treatment of steroid-resistant or gut graft-versus-host disease (gvhd)
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
MX2024000674A (en) 2021-07-13 2024-02-07 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer.
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
US20250381272A1 (en) 2022-06-22 2025-12-18 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
KR20250047766A (en) 2022-08-05 2025-04-04 주노 쎄러퓨티크스 인코퍼레이티드 Chimeric antigen receptor specific for GPRC5D and BCMA
WO2024034580A1 (en) * 2022-08-08 2024-02-15 株式会社先端生命科学研究所 Method for detecting ceacam1
PE20250928A1 (en) 2022-08-10 2025-04-02 Merck Sharp And Dohme Llc BINDING PROTEINS TO NKG2D, CD16 AND CEACAM5
KR20250139898A (en) * 2022-11-10 2025-09-23 페임웨이브 리미티드 Anti-CEACAM1 antibody for inhibition of neutrophil extracellular trap (NET)-mediated activation
CN120712102A (en) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 Chimeric antigen receptors specific for BAFF-R and CD19 and methods and uses thereof
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024165403A1 (en) 2023-02-06 2024-08-15 Philogen S.P.A. Anti-cea antibodies
CN121335923A (en) * 2023-04-13 2026-01-13 苏州逻晟生物医药有限公司 CEACAM1 Targeting Antibody and Its Uses
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
TW202541837A (en) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6013772A (en) 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
JP3490437B2 (en) 1992-01-23 2004-01-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Monomeric and dimeric antibody fragment fusion proteins
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
GB9421405D0 (en) 1994-10-21 1994-12-07 Dow Chemical Co Low voc laminating formulations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69633175T2 (en) 1995-05-23 2005-08-11 Morphosys Ag MULTIMETER PROTEINS
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
JP4843138B2 (en) * 1998-04-15 2011-12-21 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド T cell inhibitory receptor composition and use thereof
DE19852804C1 (en) 1998-11-16 1999-12-23 Christoph Wagener Pharmaceutical composition for manipulating angiogenesis
CA2383562A1 (en) * 1999-08-26 2001-03-01 Keith M. Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members
DE10016877A1 (en) 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyco) proteins with high immunoreactivity and a process for their preparation
SE0002835D0 (en) 2000-08-07 2000-08-07 Karolinska Innovations Ab Method and kit for production of monoclonal antibodies
EP1472276A4 (en) 2001-02-28 2007-05-09 Keith M Skubitz Small peptides capable of modulating the function of cd66 (ceacam) family members
US20030022292A1 (en) 2001-06-07 2003-01-30 Gray-Owen Scott D. Ligation of CEACAM1
US20060058257A1 (en) 2001-08-03 2006-03-16 Christoph Wagener Influencing angiogenesis using CD66a
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
US20030190600A1 (en) * 2002-04-05 2003-10-09 Dana-Faber Cancer Institute Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
CU23228A1 (en) 2002-04-29 2007-09-26 Ct Ingenieria Genetica Biotech FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
EP1572131B1 (en) 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
EP1558284B1 (en) 2002-10-08 2013-09-11 Immunomedics, Inc. Combination therapy with naked class iii anti-cea monoclonal antibodies and therapeutic agents
WO2005006958A2 (en) 2003-07-12 2005-01-27 Isis Pharmaceuticals, Inc. Modulation of ceacam1 expression
JP2007515949A (en) 2003-11-13 2007-06-21 ジェネンテック・インコーポレーテッド Screening assay and method of tumor treatment
EP1784425A4 (en) * 2004-06-30 2009-02-18 Centocor Inc Anti-mcp-1 antibodies, compositions, methods and uses
US8735157B2 (en) 2005-06-09 2014-05-27 Gal Markel CEACAM1 mediated protective immunity
WO2007071426A1 (en) 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical compositions with resistance to soluble cea
WO2007071422A2 (en) * 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
WO2008029271A2 (en) 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
KR101351195B1 (en) * 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 Novel immunogenic epitopes for immunotherapy
US10663464B2 (en) 2007-11-05 2020-05-26 Gal Markel CEACAM1 based point-of-care cancer diagnostic
JP5115561B2 (en) 2008-01-17 2013-01-09 日本電気株式会社 Wireless communication terminal, method, program, recording medium, and wireless communication system
PL2990421T3 (en) * 2009-04-30 2018-08-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. ANTI-CEACAM1 ANTIBODIES AND METHODS OF THEIR USE
AU2010274581B2 (en) 2009-07-21 2014-05-01 Tel Hashomer Medical Research Infrastructure And Services Ltd. A method of diagnosing cancer
RU2570554C2 (en) * 2009-08-31 2015-12-10 Роше Гликарт Аг Affinity-matured humanised anti-cea monoclonal antibodies
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
US8256790B2 (en) 2010-05-26 2012-09-04 William Olen Fortner Adjustable receiver hitch system
PL2800196T3 (en) 2011-12-27 2019-05-31 Lg Chemical Ltd Lithium battery and how to manufacture it
US20150273056A1 (en) 2012-10-12 2015-10-01 The Brigham And Women's Hospital, Inc. Enhancement of the immune response

Also Published As

Publication number Publication date
IL231931B (en) 2019-06-30
IL231931A0 (en) 2014-05-28
EP3360899B1 (en) 2023-01-25
BR112014008893B1 (en) 2022-04-26
US20140271618A1 (en) 2014-09-18
CN103987729B (en) 2017-05-31
ES2942314T3 (en) 2023-05-31
EP2744829A4 (en) 2015-06-03
US20170355781A1 (en) 2017-12-14
CN103987729A (en) 2014-08-13
WO2013054320A1 (en) 2013-04-18
AU2012322272A1 (en) 2014-04-10
KR20140069206A (en) 2014-06-09
BR112014008893A2 (en) 2017-11-28
EP2744829B1 (en) 2017-12-13
US20210070884A1 (en) 2021-03-11
RU2650869C2 (en) 2018-04-17
HK1199646A1 (en) 2015-07-10
JP2015502138A (en) 2015-01-22
AU2012322272B2 (en) 2017-08-17
CA2851762A1 (en) 2013-04-18
KR102189409B1 (en) 2020-12-14
EP3360899A1 (en) 2018-08-15
RU2014118773A (en) 2015-11-20
EP2744829A1 (en) 2014-06-25
LT2744829T (en) 2018-03-26
JP6170926B2 (en) 2017-07-26
ES2661488T3 (en) 2018-04-02
PL2744829T3 (en) 2018-06-29
PL3360899T3 (en) 2023-07-10
WO2013054331A1 (en) 2013-04-18
US11891453B2 (en) 2024-02-06
AU2012322272C1 (en) 2017-11-02
US9771431B2 (en) 2017-09-26
CA2851762C (en) 2021-11-30
WO2013054331A8 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
IN2014MN00873A (en)
TN2014000120A1 (en) Cd27l antigen binding proteins
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
MX2021015888A (en) Fusion of an antibody binding cea and 4-1bbl.
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EA030777B9 (en) Anti-alpha synuclein binding molecules
NZ706232A (en) Anti-cd3 antibodies and uses thereof
IN2014CN03936A (en)
MX382398B (en) ST2 ANTIGEN BINDING PROTEINS.
PH12015501284A1 (en) Bcma antigen binding proteins
NZ607680A (en) Novel antigen binding proteins
NZ726258A (en) Antibodies and uses thereof to detect folate receptor 1
PH12013501508B1 (en) Cea antibodies
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
TN2014000107A1 (en) Anti-aplhabetatcr antibody
NZ608318A (en) Anti-cxcl13 antibodies and methods of using the same
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
NZ594682A (en) Fully human antibodies specific to cadm1
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
MX2010001237A (en) Novel antibodies.
MX2015002465A (en) Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1).
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2012170929A3 (en) Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
WO2012106669A3 (en) Foxc1 antibodies and methods of their use
WO2013059206A3 (en) Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii)